Evidence map›Paper›PMID 27079684›Full record

ArticleFuture oncology (London, England)2016

Genome-wide association studies and epigenome-wide association studies go together in cancer control.

Mukesh Verma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Genetic and Epigenetic Regulation of Brain Organoids.Frontiers in cell and developmental biology · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Identifying Transcriptomic Signatures and Rules for SARS-CoV-2 Infection.Frontiers in cell and developmental biology · 2020
    Article
  12. Article
  13. Researches of Epigenetic Epidemiology for Infections and Radiation as Carcinogen.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2018
    Review
  14. Review
  15. Epigenetic Biomarkers in Colorectal Cancer.Molecular diagnosis & therapy · 2017
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mukesh VermaMethods & Technologies Branch, Epidemiology & Genomics Research Program, Division of Cancer Control & Population Sciences, National Cancer Institute (NCI), NIH, 9609 Medical Center Drive, Suite 4E102, Rockville, MD 20850, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Completion of the human genome a decade ago laid the foundation for: using genetic information in assessing risk to identify individuals and populations that are likely to develop cancer, and designing treatments based on a person's genetic profiling (precision medicine). Genome-wide association studies (GWAS) completed during the past few years have identified risk-associated single nucleotide polymorphisms that can be used as screening tools in epidemiologic studies of a variety of tumor types. This led to the conduct of epigenome-wide association studies (EWAS). This article discusses the current status, challenges and research opportunities in GWAS and EWAS. Information gained from GWAS and EWAS has potential applications in cancer control and treatment.

Indexed as

EpigenomicsGenome-Wide Association StudyHumansNeoplasmsbiomarkerscancerepidemiologyepigeneticsgenomicsomics technologiesoutcomepersonalized medicinepharmacogenomics

Identifiers

PMID27079684
PMCPMC5551540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.